Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial*

François, Bruno, Luyt, Charles-Edouard, Dugard, Anthony, Wolff, Michel, Diehl, Jean-Luc, Jaber, Samir, Forel, Jean-Marie, Garot, Denis, Kipnis, Eric, Mebazaa, Alexandre, Misset, Benoit, Andremont, Antoine, Ploy, Marie-Cécile, Jacobs, Alan, Yarranton, Geoffrey, Pearce, Tillman, Fagon, Jean-Yves, Chastre, Jean·2012·Critical Care Medicine

Abstract

OBJECTIVE: The type III secretion system is an important Pseudomonas aeruginosa-virulence determinant in animal models of infection and in humans. Antibody-mediated inhibition of the PcrV protein, an essential component of this system, might abrogate the Pseudomonas aeruginosa ability to damage epithelial cells, neutrophils, and macrophages, thereby limiting its pathogenicity. The objective of the trial was to determine the safety, pharmacokinetics, and ability to prevent Pseudomonas aeruginosa ventilator-associated pneumonia of KB001, a recombinant, PEGylated, engineered, human Fab' fragment that specifically binds to a Pseudomonas aeruginosa PcrV epitope and blocks its function. DESIGN: Multicenter, randomized, placebo-controlled, double-blind, phase-2a trial. SETTING: Ten intensive care units across France. PATIENTS: Thirty-nine Pseudomonas aeruginosa-colonized, but not infected, mechanically ventilated patients. INTERVENTIONS: Patients were randomized 1:1:1 to receive a single intravenous infusion of KB001, 3 mg/kg (n=13) or 10 mg/kg (n=14), or placebo (n=12). MEASUREMENTS AND MAIN RESULTS: The primary end points were KB001 safety and tolerability, assessed as treatment-related adverse-event frequency and severity. Secondary end points included serum and lung KB001 pharmacokinetics, and Pseudomonas aeruginosa pneumonia rate within 28 days of its infusion. KB001 was well tolerated and not immunogenic. The 3- and 10-mg/kg groups had respective maximum serum concentrations of 52,811-88,660 and 121,857-285,454 ng/mL, with mean elimination half-lives of 8.1 and 9.3 days. KB001 was detected in endotracheal aspirates from all patients receiving it, as early as day 1 and up to 28 days. Respective mean endotracheal aspirate/serum concentration ratios were 0.092 and 0.085 for the 3- and 10-mg/kg groups, who developed Pseudomonas aeruginosa pneumonia less frequently (33% and 31%, respectively) than placebo recipients (60%). CONCLUSIONS: KB001 was safe and well tolerated in this study, with a favorable pharmacokinetic profile and promising potential for reducing Pseudomonas aeruginosa pneumonia incidence in intensive care unit mechanically ventilated patients colonized with this bacterium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e31825334f6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 181

Metadata

Authors
François, B., Luyt, C.-E., Dugard, A., Wolff, M., Diehl, J.-L., Jaber, S., Forel, J.-M., Garot, D., Kipnis, E., Mebazaa, A., Misset, B., Andremont, A., Ploy, M.-C., Jacobs, A., Yarranton, G., Pearce, T., Fagon, J.-Y., & Chastre, J.
Venue
Critical Care Medicine
Published
2012-08
Volume
40
Issue
8
Pages
2320-2326
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2027017334
Cited by
181
References
2
FWCI
13.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial*. https://app.cochat.ai/papers/10.1097/ccm.0b013e31825334f6
The paper
François, B., Luyt, C.-E., Dugard, A., Wolff, M., Diehl, J.-L., Jaber, S., Forel, J.-M., Garot, D., Kipnis, E., Mebazaa, A., Misset, B., Andremont, A., Ploy, M.-C., Jacobs, A., Yarranton, G., Pearce, T., Fagon, J.-Y., & Chastre, J. (2012). Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31825334f6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.